Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Operating Expenses: 2019-2025

Historic Operating Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $44.9 million.

  • Allogene Therapeutics' Operating Expenses fell 37.44% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.4 million, marking a year-over-year decrease of 23.66%. This contributed to the annual value of $273.2 million for FY2024, which is 16.66% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Operating Expenses is $44.9 million, which was down 20.98% from $56.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Operating Expenses ranged from a high of $99.1 million in Q1 2023 and a low of $44.9 million during Q3 2025.
  • Over the past 3 years, Allogene Therapeutics' median Operating Expenses value was $69.5 million (recorded in 2024), while the average stood at $69.8 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Operating Expenses surged by 30.40% in 2022, and later slumped by 37.44% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Operating Expenses (Quarterly) stood at $73.9 million in 2021, then soared by 30.40% to $96.4 million in 2022, then dropped by 11.71% to $85.1 million in 2023, then dropped by 28.94% to $60.5 million in 2024, then slumped by 37.44% to $44.9 million in 2025.
  • Its Operating Expenses stands at $44.9 million for Q3 2025, versus $56.8 million for Q2 2025 and $65.2 million for Q1 2025.